

Certificate of Mailing

Patent & Trademark Office  
AUG 27 2002  
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 19, 2002.

By: Joyce Abriam Printed: Joyce Abriam

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: HUMAN LEA-MOTIF DEVELOPMENTAL PROTEIN

Serial No.: 09/892,316

Filing Date: June 26, 2001

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents  
Washington, D.C. 20231

COPY OF PAPERS  
ORIGINALLY FILED

TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Request for a Filing Receipt (1 pg.); and
3. Certificate under 37 C.F.R. §3.73(b), Revocation of Power of Attorney and Appointment of New Attorneys (2 pp.).

The fee has been calculated as shown below.

X No additional Fee is required.

\_\_\_\_ Please charge Deposit Account No. 09-0108 in the amount of : \$ \_\_\_\_\_

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 19 August 2002

Diana Hamlet-Cox  
for Richard C. Hamlet-Cox Reg No. 37,027

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166



Docket No.: PF-0213-2 DIV

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 19, 2002.

By: Joyce Abram  
Printed: Joyce Abram

COPY OF PAPERS  
ORIGINALLY FILED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hillman et al.

Title: HUMAN LEA-MOTIF DEVELOPMENTAL PROTEIN

Serial No.: 09/892,316

Filing Date: June 26, 2001

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents  
Washington, D.C. 20231

**REQUEST FOR A FILING RECEIPT**

Sir:

The United States Patent and Trademark Office is respectfully requested to issue a Filing Receipt for the above-identified patent application. Upon review of the file, Applicants discovered that a Filing Receipt has not been received from the USPTO. Applicants presume that this is an oversight by the USPTO, and therefore request issuance of a Filing Receipt to complete Applicants' official file.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 19 August 2002

Diana Hamlet-Cox Reg. No. 37,027  
for Diana Hamlet-Cox  
Reg. No. 33,302  
Direct Dial Telephone: (650) 845-4639

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166



Docket No.: PF-0213-2 DIV

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 19, 2002

By: Joyce Abriam Printed: Joyce Abriam

COPY OF PAPERS  
ORIGINALLY FILED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Hillman et al.

Title: HUMAN LEA-MOTIF DEVELOPMENTAL PROTEIN

Serial No.: 09/892,316

Filing Date: June 26, 2001

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents  
Washington, D.C. 20231

**CERTIFICATE UNDER 37 C.F.R. §3.73(b),  
REVOCATION OF POWER OF ATTORNEY AND  
APPOINTMENT OF NEW ATTORNEYS**

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8651, Frame 0750, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749	Shirley A. Recipon	Reg. No. 47,016
Jenny Buchbinder	Reg. No. 48,588	Cathleen M. Rocco	Reg. No. 46,172
Michael C. Cerrone	Reg. No. 39,132	Susan K. Sather	Reg. No. 44,316
Diana Hamlet-Cox	Reg. No. 33,302	Michelle M. Stempien	Reg. No. 41,327
Joel Harris	Reg. No. 44,743	David G. Streeter	Reg. No. 43,168
Richard C. Ekstrom	Reg. No. 37,027	Sreenivasarao Vepachedu	Reg. No. 46,395
Barrie D. Greene	Reg. No. 46,740	James M. Verna	Reg. No. 33,287
Lori L. Kerber	Reg. No. 41,113	Yu-Mei Eureka Wang	Reg. No. 50,510
Lynn E. Murry	Reg. No. 42,918		

**Please direct all correspondence to:**

Legal Department  
Incyte Genomics, Inc.  
3160 Porter Drive  
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Incyte Genomics, Inc.,  
Phone: (650) 845-4639, Fax: (650) 849-8886 or (650) 845-4166.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: August 19, 2002

By: 

Lee Bendekgey  
VP, General Counsel/Corporate Secretary